The study will compare the effects of rituximab treatment against placebo to determine if the medication can help with egg retrieval after hormonal stimulation of the ovaries. The treatment involves receiving rituximab through infusion into a vein, with a maximum daily dose of 1 gram and a total dose of up to 4 grams over a 28-day period.

Throughout the study, participants will be monitored for changes in their menstrual cycles, hormone levels, and overall health. The research will track various aspects of ovarian function, including the possibility of natural menstrual periods returning and successful egg retrieval after treatment. The total duration of participation in the study is 19 months, during which various health measurements will be taken to assess the treatment’s effectiveness and safety.

Participants in the study may receive either Cyclogest, which is a form of progesterone delivered as a pessary through vaginal use, or a placebo. The luteal phase refers to the period in the menstrual cycle after ovulation occurs and before the next period begins, a time when hormone levels are critical for supporting a developing pregnancy. By comparing these two groups, the study aims to see how supplementation affects outcomes such as pregnancy rates and various health factors during pregnancy and birth.

The treatment involves an intraovarian injection (injection directly into the ovary) of either platelet-rich plasma with growth factors or a placebo consisting of sodium chloride solution (salt water). The main purpose is to determine if this treatment can increase the number of eggs retrieved during the IVF procedure in women with reduced ovarian function.

During the study, participants will undergo one IVF cycle where they will receive a single injection of either the study treatment or placebo. The maximum amount of solution injected will be 6 milliliters, and the treatment will be administered through a standard injection procedure. The study will measure how many eggs can be collected following the treatment.

The purpose of the study is to compare the number of eggs produced and their maturity when using Corifollitropin alfa versus Follitropin beta. Participants in the study will receive one of these medications through injections. The study will monitor the number of total eggs and mature eggs, known as metaphase II (MII) oocytes, that are obtained after the ovarian stimulation process. This will help determine which medication is more effective in producing a higher number of mature eggs.

The study will take place over a period of time, with participants receiving treatment and undergoing regular monitoring to assess the outcomes. The results of this study could provide valuable information for improving fertility treatments for women experiencing infertility. The trial is expected to conclude by March 2025.

The study involves women who are part of an oocyte donation program and are between the ages of 18 and 34. These women have shown a strong response to ovarian stimulation, which means they have developed a significant number of follicles, or small sacs in the ovaries, that contain eggs. The trial is designed to be low-interventional, meaning it aims to minimize any additional procedures or risks for the participants.

Participants in the study will be randomly assigned to receive either letrozole or a placebo. The researchers will monitor the size of the ovaries and measure various hormone levels in the blood, such as oestradiol, progesterone, and testosterone, to gather information on how letrozole affects these factors. The study is expected to continue until August 2025, providing valuable insights into the potential benefits of using letrozole in this context.

The purpose of the study is to explore how these different forms and doses of progesterone affect the structure and function of the endometrium during cycles where the endometrium is artificially prepared for pregnancy. This involves looking at how the genes in the endometrium respond to the progesterone treatments. The study will compare the gene activity in the endometrium when using these treatments to the gene activity in a natural cycle without treatment.

Participants in the study will receive one of the progesterone treatments for a period of up to six months. The study will monitor changes in the endometrium by examining gene expression, which is the process by which information from a gene is used to create proteins that affect cell function. The study aims to identify any differences in gene expression between the different progesterone treatments and compare these to a natural cycle. This research could provide valuable insights into optimizing treatment for women with infertility issues.

The study will be conducted over a period of time, during which participants will take the medication orally in the form of film-coated tablets. The primary goal is to observe if pregnancy occurs during the study. Additionally, the study will look at how Metformin affects various biological markers in the blood that are related to fertility, such as cytokines and growth factors. These markers can provide insights into how the endometrium is functioning and whether Metformin is having a positive effect.

Further analysis will include examining the genetic material in endometrial tissues to see if there are changes that could predict the success of in vitro fertilization (IVF). The study will also explore how Metformin might help reduce oxidative stress, which can affect embryo implantation. Participants’ quality of life and lifestyle factors, such as diet, will also be assessed to understand their impact on the effectiveness of IVF. This comprehensive approach aims to provide a better understanding of how Metformin can support women with idiopathic infertility in achieving pregnancy.

The purpose of the study is to compare the effectiveness of these two treatments in helping retrieve mature eggs, known as metaphase II oocytes, during a specific type of fertility treatment cycle called progesterone-primed ovarian stimulation. Participants in the study will receive either the nafarelin nasal spray or the triptorelin injection. The study will monitor the number of mature eggs retrieved, as well as other factors like the total number of eggs collected, any side effects, and the participants’ experiences with the treatments.

The study will take place over a period of time, with participants undergoing the treatment and then having their eggs collected. The researchers will gather data on the outcomes to determine which treatment is more effective or if they are equally effective. This information could help improve fertility treatments for individuals experiencing infertility.

The purpose of the study is to determine which type of contrast media is more effective in helping women achieve a successful pregnancy. The study will follow participants for up to six months after the procedure to see if they become pregnant and have a live birth. Participants will be randomly assigned to receive either the oil-based or water-based contrast media during their HSG procedure. Some participants may receive a placebo, which is a substance with no active ingredients, to compare the effects.

Throughout the study, various outcomes will be monitored, including the time it takes to become pregnant, any complications from the HSG procedure, and the health of the pregnancy and newborn. The study aims to provide valuable information on the best approach to using contrast media in HSG for women experiencing infertility, ultimately helping to improve their chances of conceiving and having a healthy baby.

The purpose of the study is to compare the levels of a hormone called progesterone and the ratio of progesterone to another hormone called estradiol on the day when ovulation is triggered. This is done to see if adding rhLH to the treatment makes a difference in hormone levels and the overall response to the treatment. The study will also look at other factors, such as the number of eggs retrieved, the quality of embryos, and the chances of achieving a pregnancy.

Participants in the study will follow a specific treatment plan over a period of time, which includes receiving injections of the study medications. The study will monitor hormone levels and other indicators at various points to gather information on how the treatments are working. The goal is to find the most effective approach for women who have had a suboptimal response to previous fertility treatments.

The purpose of the study is to find the best dosing of recombinant FSH (follicle-stimulating hormone) after using corifollitropin alfa in women undergoing In Vitro Fertilization (IVF) or ICSI. Participants will receive these medications through subcutaneous injections, which means the medication is injected under the skin. The study will compare different doses to see which one works best in helping women produce eggs for IVF or ICSI.

Throughout the study, researchers will monitor the levels of a hormone called progesterone in the blood on a specific day of the treatment cycle. They will also look at other outcomes, such as the number of eggs retrieved, the rate of clinical pregnancies, ongoing pregnancies, miscarriages, and live births. The study aims to provide valuable information on how to optimize treatment for women undergoing fertility treatments.

The purpose of the study is to determine if there is a difference in the number of healthy embryos that can be obtained using these two different methods. Participants in the study will undergo a process called embryo accumulation, where multiple eggs are collected and fertilized to create embryos. These embryos are then tested to ensure they have the correct number of chromosomes, a process known as PGT-A (Preimplantation Genetic Testing for Aneuploidies). The study will compare the effectiveness of the two methods in producing embryos that are suitable for this testing.

Participants will be divided into two groups, with each group receiving one of the two treatments. The study will last for a period of time during which participants will receive the medication and undergo the necessary procedures. The goal is to see which method results in a higher number of healthy embryos. This information could help improve treatment options for women experiencing infertility.

The main treatment being tested is Testogel, a gel that is applied to the skin and contains testosterone. This medication will be used before starting the fertility treatment. Additional medications used in the study include Decapeptyl, Bemfola, and Astarté, which are all given as injections under the skin to help stimulate and control egg production.

The purpose of this study is to determine if using testosterone gel before fertility treatment can increase the number of eggs collected during the procedure in women who have both low ovarian reserve and a specific genetic variation. The study will measure various aspects of fertility treatment success, including the number and quality of eggs obtained, how well the eggs develop after fertilization, and whether pregnancy occurs.

The purpose of the study is to determine if this additional tubal flushing with the oil-based contrast after undergoing Hyfosy can significantly increase the likelihood of a live birth within six months. Participants in the study will be randomly assigned to either receive the additional tubal flushing or not, allowing researchers to compare the outcomes between the two groups.

Throughout the study, participants will be monitored from the first day of their last menstrual cycle in which they conceive, up to six months after undergoing Hyfosy. The main focus is on the occurrence of a live birth during this period. This study aims to provide valuable insights into whether this additional procedure can be beneficial for women facing fertility challenges.

The purpose of the study is to evaluate how these different approaches affect the chances of having a live birth after IVF. Participants in the study will be randomly assigned to one of the treatment groups: exercise and Mediterranean diet, aspirin, or no intervention. The study will monitor the participants over a period to see which approach leads to a higher rate of live births.

Throughout the study, participants will follow their assigned treatment plan, and their progress will be observed to determine the effectiveness of each approach. The ultimate goal is to find out which method is most beneficial for improving live birth rates in women undergoing IVF. This information could help guide future treatment options for women facing infertility challenges.

Participants in the study will receive either 15 micrograms or 20 micrograms of follitropin delta. The study will monitor the number of healthy embryos, known as euploid embryos, that develop. The trial will also look at other factors such as the total dose of medication used, the number of eggs retrieved, and various hormone levels during the process. The study aims to provide insights into the best approach for ovarian stimulation in women who are undergoing fertility treatments.

The trial will involve a series of injections and oral medications over a period of time, with regular monitoring to assess the development of embryos. The study will help determine the most effective treatment plan for women experiencing infertility, particularly those who are older and seeking to improve their chances of having a successful pregnancy. The findings from this study could lead to better treatment options for women facing similar challenges.

The study involves several medications that are administered as injections. REKOVELLE contains the active substance follitropin delta, while MENOPUR contains menotrophin. Other medications used in the study include Fyremadel with the active substance ganirelix, Decapeptyl with triptorelin acetate, and Ovitrelle with choriogonadotropin alfa. These medications are given through subcutaneous injections, which means they are injected under the skin.

Participants in the study will receive these medications over a period of time to stimulate their ovaries. The main goal is to observe the number of fertilized eggs, known as oocytes, after insemination. The study is designed to be randomised, meaning participants are randomly assigned to different treatment groups, and it is controlled, which means it includes a comparison group. The trial is also assessor-blind, meaning the people assessing the outcomes do not know which treatment the participants received, to ensure unbiased results.

The purpose of the study is to determine if adding progesterone support during a specific phase of the menstrual cycle, known as the luteal phase, can increase the chances of a live birth for couples undergoing a fertility treatment called intra-uterine insemination (IUI) with mild ovarian stimulation. This involves using a medication called FSH to gently stimulate the ovaries. The study will follow participants over a period of six months to observe outcomes such as pregnancy rates, live births, and any side effects experienced during the treatment.

Participants in the study will be monitored for various outcomes, including the number of IUI cycles they undergo, any pregnancies that occur, and the overall impact on their quality of life. The study will also assess the cost-effectiveness of adding progesterone support to the treatment. The findings from this study aim to provide valuable insights into improving fertility treatment outcomes for couples facing unexplained infertility.

Participants in the study will receive one of the following treatments: Bemfola, which contains the active substance follitropin alfa and is given as an injection under the skin; Duphaston, which contains dydrogesterone and is taken as a tablet by mouth; or Gonapeptyl Daily, which contains triptorelin acetate and is also given as an injection under the skin. Some participants may receive a placebo. The study will last for a period of up to 21 days, during which the effectiveness of these treatments in stimulating the ovaries will be assessed.

The purpose of this study is to find out if the new method of ovarian stimulation is as effective as the traditional method in producing mature eggs that can be frozen. Participants will be monitored throughout the study to track the number of eggs retrieved and the amount of medication used. The study aims to provide valuable information that could help improve fertility preservation techniques for women in the future.